This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Mayne Pharma Group Future Growth

Future criteria checks 1/6

Key information

73.5%

Earnings growth rate

82.4%

EPS growth rate

Pharmaceuticals earnings growth	36.9%
Revenue growth rate	9.2%
Future return on equity	n/a
Analyst coverage	Low
Last updated	n/a

Recent future growth updates

No updates

Recent updates

No updates

Earnings and Revenue Growth Forecasts

CHIA:MYXDA - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2025	522	-45	17	65	3
6/30/2024	479	-69	-91	4	4
6/30/2023	350	-70	615	31	4
6/30/2022	425	-263	-19	-7	N/A
3/31/2022	407	-170	-13	3	N/A
12/31/2021	388	-78	-7	13	N/A
9/30/2021	395	-143	14	36	N/A
6/30/2021	401	-208	34	59	N/A
3/31/2021	420	-232	56	82	N/A
12/31/2020	439	-256	78	106	N/A
9/30/2020	448	-174	72	109	N/A
6/30/2020	457	-93	65	113	N/A
3/31/2020	467	-196	61	109	N/A
12/31/2019	478	-300	56	106	N/A
9/30/2019	502	-290	40	106	N/A
6/30/2019	525	-279	25	107	N/A
3/31/2019	543	-118	28	117	N/A
12/31/2018	561	43	31	127	N/A
9/30/2018	546	-46	29	124	N/A
6/30/2018	530	-134	27	121	N/A
3/31/2018	526	-146	-12	111	N/A
12/31/2017	521	-158	-50	100	N/A
9/30/2017	547	-35	-575	42	N/A
6/30/2017	573	89	-1,099	-15	N/A
3/31/2017	504	90	-1,089	-30	N/A
12/31/2016	435	91	-1,078	-44	N/A
9/30/2016	351	64	-544	5	N/A
6/30/2016	267	37	-9	54	N/A
3/31/2016	238	30	N/A	49	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MYXDA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MYXDA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MYXDA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MYXDA's revenue (9.2% per year) is forecast to grow faster than the Australian market (3.6% per year).

High Growth Revenue: MYXDA's revenue (9.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MYXDA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/01/25 07:57
End of Day Share Price	2023/01/24 00:00
Earnings	2022/06/30
Annual Earnings	2022/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mayne Pharma Group Limited is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Russell Wright	APP Securities Pty Ltd.
Russell Wright	Barclay Pearce Capital Pty Limited
John Hester	Bell Potter